Home › Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
 

Keywords :   


Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

2014-02-03 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK (Timothy grass pollen allergen extract) sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: approval canadian grass extract

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Bank of England plans expansion of Leeds base
17.05Henkel Laundry Patent Details Transfer of Encapsulated Fragrance with Dryer Balls
17.05The Recycling Partnership Welcomes McDonalds Corporation to the Polypropylene Recycling Coalition and Awards its 100th Recycling Facility Grant
17.05Cooking temperatures sufficient to kill H5N1 in meat
17.05This Week in Waste: Top Stories May 13 May 16, 2024
17.05New Pizza Box Recycling Bins Rolling Out in Central Park, Aiming to Limit Rodent Issues
17.05WM Celebrates Completion of $23 Million in Upgrades at Pittsburgh Facility
17.05Bioenergy Devco's Maryland Bioenergy Center Recycles Food Waste at Full Nameplate Capacity
More »